secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001376339-25-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q1 net sales $88M (+4% YoY); GAAP EPS $0.05; reaffirms high single-digit growth outlook
--------------------------------------------------------------------------------

- Net sales $88M (+4% YoY); GAAP net income $7M ($0.05 EPS); Adj. EBITDA $17M (20% margin).
- Gross margin fell to 81% from 85% on product mix; Surgical products grew 16%, Wound fell 2%.
- Cash $106M; net debt $0; 2025 outlook: high single-digit sales growth and >20% Adj. EBITDA margin.
- CEO calls LCD delay disappointing; added CELERA product as contingency for affected settings.
- SG&A rose to $60M from $55M on higher commissions, salaries, and legal/regulatory costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000137633925000044/0001376339-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000137633925000044/mdxg-20250430.htm
  HTML page:      https://secwatch.observer/filing/0001376339-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer